164
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
DEVELOPMENT OF TECHNOLOGY FOR THE BIOLOGICAL ACTIVE ADDITIVE
"DEPRESSFAN" WITH A CALMING EFFECT
Shermatova Kh.B.
Umarova F.A.
Tashkent Pharmaceutical Institute, Tashkent, Republic of Uzbekistan
https://doi.org/10.5281/zenodo.17328700
Relevance:
Biologically active supplements (BAS) are the most effective way to eliminate
vitamin and mineral deficiencies, provided that the supplements contain biological substances in
doses that meet the physiological needs of the human div.
The State Policy Concept of the Republic
of Uzbekistan on Healthy Nutrition stipulates that expanding the use of dietary supplements to
improve the nutritional structure is an urgent measure. In addition, the concept implies the creation
of new, scientifically substantiated formulations of dietary supplements. It is known that sedatives
include medications and dietary supplements that have a general calming effect on the nervous system
by reducing excitation processes. In addition, sedatives are used in combination with other
medications in the early stages of treatment for various diseases.
Research objective:
Based on this, the aim of this work was to develop a technology for a
calming dietary supplement called Depressphan, which is a tablet made from a mixture of dry
extracts.
Materials and methods:
Ready-made dry extracts approved for medical use were used in the
development: motherwort (FSP-221759413142-2022), St. John's wort (GF RUz III-volume, 1-part,
pp.14-143), rhizome with valerian roots (FSP-221759413142-2022), Regel's zopnik (certificate
compliance), Ginkgo biloba leaves (VFS 42-Uz-5462-2024). Excipients: potato starch, lactose 80M,
Intracel MCC, sodium hydrocarbonate, Aerosil A-380, maltodextrin, calcium stearate, magnesium
stearate. As a binding agent: purified water, 3-5-7% starch paste, and various types of ethyl alcohol.
The finished dry extracts are fine-grained powders with a specific odor.
Results:
At the first stage of tablet development, 5 dry extracts were weighed with an accurate
weight and sieved through a 1000 μm sieve, and then each extract was combined. The composition
of the mixture of dry extracts was called "Depressfan".
Next, 5 different formulations were obtained
under standard conditions. The results of the experiment showed that it is advisable to use a 5% starch
paste as a binding agent when preparing tablets using the wet granulation method. Next, to obtain
model compositions of "Depressfan" tablets, an exact amount of a composition of dry extracts and
auxiliary substances was weighed according to the corresponding formulations. All the components
were thoroughly mixed and passed through a 160-micron sieve, and a 5% starch paste was added in
three stages and thoroughly mixed. The wet mass was passed through a sieve with a hole of 1000 μm
and spread in a layer of 1-1. 5 cm on the shelves of a drying cabinet. 55-60°C was dried to an optimal
humidity of 5.0%. The resulting granulate was then powdered with magnesium stearate. The resulting
tablet mass was tabletized using a Retsch PP 25 manual hydraulic tablet press with an 8 mm press
tool. The quality of model tablets obtained from prepared masses was evaluated, and their
technological properties were studied using the methods described in the literature.
Conclusions:
As a result of the research, an optimal technology for obtaining Depressfan 0.5 g
in the form of tablets using the wet granulation method has been developed. The quality assessment
of the tablets was carried out in accordance with the State Pharmacopoeia of the Republic of
Uzbekistan, Volume I. The obtained tablets containing Intracel microcrystalline cellulose, starch, and
165
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
magnesium stearate as auxiliary substances fully meet the requirements of the State Pharmacopoeia
of the Republic of Uzbekistan.
